Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
EMD Serono
Boehringer Ingelheim
Centre Oscar Lambret
Seagen Inc.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Gruppo Oncologico del Nord-Ovest
UNICANCER
Allama Iqbal Medical College
Harbin Medical University
Servier
Henry Ford Health System
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enliven Therapeutics
National Cancer Centre, Singapore
Shenyang Sunshine Pharmaceutical Co., LTD.
Rutgers, The State University of New Jersey
Akeso
BeiGene
Jazz Pharmaceuticals
Korea University Anam Hospital
Oslo University Hospital
Pfizer
GERCOR - Multidisciplinary Oncology Cooperative Group
AstraZeneca
Cancer Trials Ireland
Qilu Pharmaceutical Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
McGill University Health Centre/Research Institute of the McGill University Health Centre
Seattle Project Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Fudan University
Vejle Hospital
Ludwig-Maximilians - University of Munich
Nizhny Novgorod Regional Clinical Oncology Center